Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A major collaborative study, in which DPAG’s Dr James Grist plays a key role, involving teams in the universities of Oxford, Sheffield, Cardiff and Manchester, has identified abnormalities in the lungs of Long Covid patients who are experiencing breathlessness. Researchers are using a novel xenon gas scanning method to locate damaged areas that cannot be detected by routine scans.

Increased brighter areas of gas activity can be seen on the healthy scan, whereas there are more 'dark' areas suggesting impaired gas activity on the patient scan. © University of Oxford

The EXPLAIN study has used hyperpolarised xenon MRI scans to uncover evidence of lung damage in a small group of people who were not hospitalised with Covid-19 yet continue to experience breathlessness long after initial infection. These abnormalities had previously not shown up on standard Computed Tomography (CT) scans. 

The work builds on an earlier study that used the same cutting-edge method of imaging to find persistent lung abnormalities in patients who had been admitted to hospital with Covid-19 several months after they were discharged.

Hyperpolarised xenon MRI is a safe scanning test that requires the patient to lie in the MRI scanner and breathe in one litre of the inert gas xenon that has been hyperpolarised so that it can be seen using MRI. As xenon behaves in a very similar way to oxygen, radiologists can observe how the gas moves from the lungs into the blood stream. The scan takes just a few minutes and, as it does not require radiation exposure, it can be repeated over time to see changes to the lungs.

These initial results show that there is “significantly impaired gas transfer” from the lungs to the bloodstream in these long COVID patients when other tests are normal.

DPAG Postdoctoral Research Scientist Dr James Grist, who has been running the scans and image analysis, said: “It’s real breakthrough that we can detect abnormalities in gas handling in the lungs of people that have never been hospitalised with COVID, yet now suffer from long COVID, in particular breathlessness. We cannot seem to find anything wrong on their normal CT scans, and yet here we can clearly see that there is something not right with our imaging technique. This is particularly useful because it may start to shed some light on why some people experience the symptom of breathlessness long after COVID, and will allow us quantitatively measure the effect of any therapies used to try and reverse this.”

Long Covid refers to a host of symptoms that continue for many weeks after a coronavirus infection and cannot be explained by another cause. More than a million people in the UK continue to experience symptoms months after having COVID-19, with breathlessness one of the most commonly reported symptoms.

A larger, more detailed study is under way to confirm the results. The full EXPLAIN study, supported by the NIHR Oxford Biomedical Research Centre (BRC), will recruit around 400 participants: 200 long COVID patients with breathlessness, along with 50 patients who have had COVID-19 but now have no symptoms at all; 50 patients who have no breathlessness, but do have other long COVID symptoms, such as ‘brain fog’; and 50 people who have never had long COVID who will act as controls for comparison. It is one of 19 studies that have received nearly £40 million investment from the National Institute for Health Research (NIHR) to improve understanding of long COVID, from diagnosis and treatment through to rehabilitation and recovery.

More information about the study and can be found on the NIHR Oxford BRC website.

The story has been covered by the BBCSky News, The Guardian, and many more publications and outlets.

Similar stories

REF 2021 results

DPAG researchers showcased at premier European Society of Cardiology meeting

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

DPAG Postdoctoral Researcher acknowledged for developmental and cell biology research

Dr Matthew Stower was selected to give an oral presentation of his work and his abstract won the second prize at the Joint Spring Meeting of the British Society for Developmental Biology (BSDB) and the British Society for Cell Biology (BSCB).

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.